Leo Pharma and Astrazeneca keep future plans tight for tralokinumab
Neither Leo Pharma nor Astrazeneca wants to reveal the future plans for tralokinumab, which has just been approved as an atopic eczema treatment in the US. The drug has blockbuster potential in the approved indication, and while other indications might be considered, Astrazeneca retains the rights for several lucrative indications.
Jörg Möller, head of global research and development at Leo Pharma, doesn't have a lot to say when it comes to Leo Pharma's hopes for tralokinumab besides atopic eczema
by ULRICH QUISTGAARD, translated by daniel pedersen
The US approval of Leo Pharma's eczema drug, tralokinumab, has been a popular topic at the Danish dermatology firm, which has clear blockbuster expectations for the treatment.
Per Wold-Olsen left the chairperson position two weeks ago after 15 years – he now reveals there haven’t been acquisition talks behind closed doors during his time at the company.
Per Wold-Olsen left the chairperson position two weeks ago after 15 years – he now reveals there haven’t been acquisition talks behind closed doors during his time at the company.
Microsoft is in the process of discontinuing Internet Explorer – and so are we. For a better experience, we recommend using one of the following browsers.